MacroGenics gets $15M from Gilead; Zenas, Bristol Myers sign licensing deal in Asia-Pacific

MacroGenics is set to receive a $15 million milestone payment from Gilead, which is using the company’s two bispecific antibody platforms in a research program. The program will be led by MacroGenics and funded by Gilead.

The original partnership was struck in October 2022. MacroGenics is still entitled to receive up to $1.7 billion from the deal. The partnership also covers MacroGenics’ CD123- and CD3-targeting bispecific antibody MGD024 and two other bispecific research assets. — Anna Brown

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Emergent BioSolutions CEO Robert Kramer announces retirement

Robert Kramer, the CEO of contract manufacturer Emergent BioSolutions, is retiring after more than two decades, including leading the company through a sometimes-turbulent Covid-19 pandemic.

June 28, 2023

NYU Langone Health’s Back-to-School Drive provides vital support for Brooklyn and Long Island students

On August 28, the Family Health Centers at NYU Langone Health held its 20th annual Back-to-School Drive at the Martin Luther Playground on 55th Street

September 20, 2024

J&J trims pipeline, including two mid-stage neuroscience studies

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.